New combo therapy aims to shrink untreatable liver tumors
Disease control
Recruiting now
This phase 2 trial tests whether a combination of radioactive beads (yttrium-90), an immunotherapy drug (camrelizumab), and a targeted therapy (apatinib) works better than standard chemoembolization for liver cancer that cannot be surgically removed. About 120 adults with non-met…
Phase: PHASE2 • Sponsor: GrandPharma (China) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC